Receive our newsletter – data, insights and analysis delivered to you
June 15, 2009

GSK and Dr Reddy’s Strike Emerging Market Alliance

GlaxoSmithKline (GSK) and pharmaceutical company Dr Reddy's have forged a strategic alliance to develop and market pharmaceutical products across emerging markets, excluding India. Under the agreement, GSK will gain exclusive access to Dr Reddy's portfolio and future pipeline of more than

By cms admin

GlaxoSmithKline (GSK) and pharmaceutical company Dr Reddy’s have forged a strategic alliance to develop and market pharmaceutical products across emerging markets, excluding India.

Under the agreement, GSK will gain exclusive access to Dr Reddy’s portfolio and future pipeline of more than 100 branded pharmaceutical products.

The current and future pipeline products will fall under the cardiovascular, diabetes, oncology, gastroenterology and pain management categories.

GSK president of emerging markets Abbas Hussain said that growth in population and economic prosperity is leading to increased demand for branded pharmaceuticals in emerging markets.

“This new alliance will combine Dr Reddy’s portfolio of quality branded pharmaceuticals together with GSK’s extensive sales and marketing capabilities,” Hussain said. “Together we will be able to deliver more medicines of value to more patients in these countries.”

The products will be manufactured by Dr Reddy’s and licensed and supplied by GSK in various countries in Africa, the Middle East, Asia Pacific and Latin America. In certain markets, products will be co-marketed by both companies.

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Under the terms of the agreement, revenues will be reported by GSK and shared with Dr Reddy’s.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU